Hypogonadism is a recognised cause of osteoporosis in men. When patients with advanced prostate cancer are treated with luteinising hormone releasing hormone (LHRH) agonist analogues their circulating testosterone levels decline and these patients may develop fractures.
Introduction
Osteoporosis is now recognised as an important health care problem in men; it is associated with an increasing incidence of hip fracture. Cross-sectional studies on the aetiology of male osteoporosis have revealed important risk factors such as corticosteroid and anticonvulsant treatment, family history of osteoporosis, current smoking, high alcohol consumption and hypogonadism. 1, 2 In patients with osteoporosis secondary to hypogonadism, the role of oestrogen and its formation from testosterone are key factors. 3 Also, hypogonadism in men is associated with accelerated bone remodelling and an increase in circulating levels of biochemical bone markers. 4 -6 This is a phenomenon similar to that seen in post menopausal women, and in recent studies androgen replacement has been associated with changes in bone turnover and increase in bone density. 7 Metastatic prostate cancer is commonly treated with androgen deprivation treatment involving surgical orchidectomy or medical castration using luteinising hormone releasing hormone (LHRH) analogues. 8 These patients are particularly at risk of osteoporosis as they are usually older, when bone loss in men occurs. Also, they have therapeutically induced low circulating testosterone concentrations making them vulnerable to osteoporosis and which may produce changes in bone turnover. 9 Bone loss and fractures have been reported in these situations. 10, 11 The side effect profile of LHRH agonists reflects the hypogonadal state that is produced. There is reduction in muscle mass, libido and potency as well as hot flushes, gynaecomastia, fatigue and weight gain, although the effect on skeletal homeostasis is less well known.
This paper describes a cross-sectional study on a cohort of patients with prostate cancer, treated with the LHRH agonist analogue, goserelin. They have been compared to patients with prostate cancer not on androgen deprivation treatment and also to a group of elderly males living in the community. The objective was to determine the degree of bone loss and bone turnover in the treated patients so that a strategy preventing bone loss in these patients could be formulated, thus improving the quality of life of patients with advanced prostate cancer.
Patients and methods
Patients with histologically proven adenocarcinoma of the prostate gland were identified from a urology out patient clinic (Group 1). Only patients receiving LHRH agonist therapy with goserelin (Zoladex (Astra Zeneca UK Ltd, Herts) 3.6 mg subcutaneously every 28 days or 10.8 mg subcutaneously every 90 days), n ¼ 42 were assessed for osteoporosis and bone turnover so that anti-bone resorptive treatment could be administered subsequently.
Patients identified as having osteoporosis (bone density T-score values less than 72.5) were offered referral to the Osteoporosis Clinic, where some of these patients were given lifestyle advice and anti-bone resorptive treatment. Data from patients when on these treatments were not included in the analysis described. Histological grading by Gleason score and pre-treatment serum prostatic specific antigen (PSA) were documented and the presence of metastases determined by radionuclide bone scan. There was an even distribution in terms of Gleason grading with a median value of 5 and patients had been on treatment for at least six months and in some cases as long as 6 y (mean length of treatment, 26 months (20 -33, 95% CI). Routine monitoring of response to treatment included serum PSA and testosterone. All patients had basic biochemical tests of mineral metabolism performed at initial assessment, to exclude metabolic bone diseases such as Paget's disease and osteomalacia.
PSA was measured by heterogeneous sandwich magnetic separation assay (male reference range 0.4 -4.0 ng/ ml, between batch CV < 4%) and testosterone by competitive magnetic separation immunoassay (male reference range 10.0 -38.0 nmol/l between batch CV, 5%) (Immuno 1, Bayer Diagnostics, Tarrytown, USA).
Bone formation was assessed by measurements of serum bone specific alkaline phosphatase (bALP) using an immunocapture enzymatic assay (Alkphase B, Metra Biosystems USA, male reference range 15.0 -41.3 u/l, between batch CV < 8%), and bone resorption by urine N-telopeptide crosslinks of type 1 collagen (NTX, Osteomark, Ostex International, Seattle, WA, USA, male reference range up 51 BCE/mmol creatinine, between batch CV < 9%). Forearm bone density was assessed by dual energy X-ray (DEXA) forearm bone densitometry (DTX 200, Osteometer Meditech, A/S, Roedoure, Denmark) correlation with Lunar DXA, lumbar spine, r ¼ 0.53, P < 0.001, femoral neck, r ¼ 0.54, P < 0.001. 12 The information obtained was compared with that from a group of patients with clinically localised carcinoma of the prostate (Group 2; biochemistry only) n ¼ 20, treated without hormone manipulation. These patients had a serum total PSA less than 25 ng/ml at diagnosis and were bone scan negative (n ¼ 20). The patients were also compared with a group of 91 active elderly men, (bone density and urine bone resorption marker; Group 3), living in the community. They had serum PSA values within the age matched reference range and no lower urinary tract symptoms, and were assessed as part of the Out Reach Osteoporosis Service. Blood samples were not available from these subjects but their general health was closely monitored by an on site medical service (Table 1) .
Statistical method
The correlation between bone markers and age and bone density in each group was assessed by Pearson correlation, and means of groups were compared by Student's t-test assuming unequal variances.
Results
The mean age of the patients included in the study was similar, but there were statistical differences between the groups. (Group 1 vs Group 2, P < 0.05, Group 1 vs Group 3 P < 0.05, Group 2 vs Group 3 P < 0.01). As expected there was a significant difference in serum testosterone values between the goserelin treated patients (Group 1) and those not on Zoladex treatment (Group 2) P < 0.0001.
There was no difference between the mean bone density (BMD) values for Group 1 and Group 3 patients (0.479 (0.016), mean (s.e.) g/cm 2 , and 0.479 (0.009)) and 41.9 (6.1) 20.7 (1.5)** Serum testosterone (nmol/l) 0.83 (0.05) 13.4 (1.6)*** *P < 0.01; **P < 0.002; ***P < 0.0001.
there was a similar distribution of patients which were osteoporotic, osteopenic and normal according to the WHO criteria: 13 Group 1, 50% osteoporotic T score < 72.5, 28% osteopenic, T score between72.5 and71.0, 22% normal, T score > 71.0; Group 3, 42% osteoporotic, 38% osteopenic and 20% normal (see Table  2 and Figure 2 ). There was no significant relationship between length of time on treatment and bone density in Group 1. However, the bone marker values (Figures 1 and  2) were significantly higher in Group 1 compared with Groups 2 and 3: NTX, 80.1 (9) BCE/mmol, mean (s.e.) Group 1; 42.6 (7.6) Group 2; 30.1 (2.9) Group 3, P < 0.01 and P < 0.0001; and bALP, 41.9 (6.1) u/l Group 1; 20.7 (1.5) Group 2, P < 0.002. This represented increased bone turnover in the patients on goserelin with low serum testosterone compared to the patients not on goserelin. The patients in Group 1 who had positive radionuclide bone scans (n ¼ 14) did not have significantly different bone marker values compared to those patients with negative scans in Group 1. The bone marker N terminal end (NTX) values in the elderly untreated men correlated with age (P < 0.001) but in the goserelin treated patients this relationship was not present.
Discussion
This study of patients with prostate cancer treated with LHRH analogues shows that a significant number of the patients had osteoporosis from forearm pDEXA measurements, together with high urine NTX values suggesting high bone turnover. If these findings are secondary effects of the treatment, it may be possible to prevent them with the use of anti-bone resorptive agents such as bisphosphonates. However, it is important to clarify whether the bone loss and increased bone turnover occurs in normal men as they age, is a specific effect of the reduction in serum testosterone produced by the treatment, or could be related to the presence of skeletal metastases from the prostatic carcinoma.
Information on bone loss and bone turnover in normal ageing men is only just emerging. Our study shows no difference in bone density between the LHRH treated patients with hypogonadism and the elderly men living in the community. This suggests that the bone loss detected may be part of the normal ageing phenomenon and that the reduction in testosterone secretion may exacerbate the normal physiological phenomenon. A corollary would be the enhanced risk of osteoporosis in postmenopausal women treated with corticosteroids for inflammatory disease. Changes in bone turnover may occur with age in men 14, 15 and are correlated with levels of bone mass in both men and women. 16 In our Figure 1 Urine NTX, (mean (s.e.)) in Groups 1, 2 and 3. *P < 0.01, **P < 0.0001 compared with Group 1. patients treated with goserelin (Group 1) NTX values did not correlate with age or bone density, whereas these relationships were present in the elderly untreated men (Group 3); P < 0.001 age; P < 0.05 bone density.
Hypogonadism following castration produces rapid bone loss in the 5 y following surgery 4 and patients with prostate cancer treated with orchidectomy or LHRH agonists may develop osteoporosis with fractures. 10, 11 It is likely that this is related to the iatrogenic hypogonadism and resulting low serum testosterone concentrations.
In a telephone survey of 224 patients receiving LHRH agonists for prostate cancer, a 5% incidence of osteoporotic fracture was reported. 17 The rate of bone loss following commencement of androgen deprivation has been estimated at 4% per year. 18 This rate was found to fall to 2% in men who had received androgen deprivation for more than 3 y and compared to a slight increase in matched controls. Similar results were found by Maillefert et al who reported falls in bone density of 3% at 6 months, rising to 7% by 18 months. 19 This loss of bone density approximates to values seen in women following oopherectomy or post-menopause 20 and compares to a loss of 0.5% per year in normal age matched men. 21 In addition to bone density the risk of fracture relates to other factors including body mass, exercise and diet. Obese patients may have an increased bone density due to peripheral oestrogen conversion of testosterone. Interestingly, it may be that these patients suffer a relatively more rapid fall in bone density following hormonal deprivation. 18 Regular exercise, diet and alcohol intake may all modify the effects of androgen deprivation on bone density. 22 When LHRH agonists are given to premenopausal women with endometriosis producing postmenopausal low serum oestrogen levels after three months, there is a significant decrease in bone mineral content with increased indices of bone turnover. 23 Also, in elderly men with benign prostatic hypertrophy, long acting LHRH agonist treatment caused a state of testosterone deficiency which resulted in bone loss in at least 50% of patients in 1 y, which was accompanied by enhanced bone turnover. 5 The bone loss in our patients with prostate cancer with medical castration and that present in the elderly men with probable physiological decline in serum testosterone with age, is likely to be due to a similar mechanism. The increase in bone turnover found in Group 1 may be due to the severe androgen deprivation. Biochemical markers of bone turnover, such as urinary collagen degradation products, rise after the menopause in women, 24 following a relatively acute fall in the circulating levels of oestrogen. In men the decline in testosterone with age is much more gradual in comparison, but in men treated with LHRH agonists the reduction in testosterone is very acute 5, 9 and somewhat parallel to the changes occurring in women at the menopause.
Bone marker changes are also of interest as potential indicators of skeletal metastases. Degradation of type 1 collagen occurs with bone resorption and the products are released into the circulation and excreted in the urine. These substances may be measured as either the C terminal end (Crosslaps, CTX) or N terminal end (NTX) of the telopeptide of type 1 collagen. In patients with prostate cancer, the rate of excretion of urinary Crosslaps is greater in patients with bone metastases than in those without 25 and markers of bone turnover have been used to monitor the effect of intravenous bisphosphonate in such patients. 26 It is difficult to be sure that the elevated bone marker changes in our patients are due to increased bone turnover due to hypogonadism rather than skeletal metastases. The majority of prostatic bony metastases are osteosclerotic in nature and typically this is reflected by elevated markers of bone formation. Despite the predominantly osteosclerotic nature of metastases markers of both bone resorption and formation are elevated in metastatic disease. 26, 27 The evidence of increased bone resorption in bone metastases forms the basis of the clinical use of bisphosphonates in this setting. The use of intravenous pamidronate in metastatic prostate cancer has been shown to reduce urinary and serum resorption markers by between 65 and 70%. The bALP in our patients was higher in the patients with advanced disease (Group 1) compared to those with localised disease (Group 2), P < 0.002. However, the patients with evidence of metastases on testing by radionuclide scan did not have statistically higher NTX or bALP values than patients with negative scan results.
The findings in this study raise the question of whether patients treated with LHRH analogues for prostate cancer, need protection against development of osteoporotic fractures.
From studies in women, oestrogen deficiency after spontaneous or artificial menopause results in an increase in bone remodelling which, if sustained, results in a faster bone loss than usual and an increased risk of osteoporosis. 24, 28 Women with bone marker values 2 s.d.s greater than the mean have a 75 -80% probability of rapid bone loss compared with women with values 2 s.d.s below the mean, who have a 20 -25% probability of rapid bone loss. 29, 30 In the recent OFELY study, women with levels of bone markers at baseline, 2 s.d. above the mean of premenopausal women, had a highly significant rate of forearm bone loss that was 2 -6 fold higher than in women with a low bone turnover, 31 and in the recommendations for the use of bone markers in postmenopausal osteoporosis produced by the Committee of Scientific Advisers of the International Osteoporosis Foundation, 32 it is stated that high levels of bone resorption markers are associated with an approximately 2-fold increased risk of osteoporotic fractures. Therefore, the patients described in this study who were treated with LHRH analogues and had a subsequent acute reduction in testosterone secretion, can be likened physiologically to women at the menopause. The high urine NTX values represent high bone turnover and it is reasonable to expect that these patients (Group 1) have an increased risk of osteoporotic fractures compared to male subjects of a similar age with lower bone turnover (Group 3).
The WHO definition of osteoporosis and the Royal College of Physicians of London clinical guidelines for prevention and treatment of osteoporosis relate mainly to the disorder in women. However, there is little to suggest that men and women respond differently to therapeutic intervention. In clinical practice, prevention and treatment of osteoporosis can be considered as a continuum involving regular weight-bearing exercise, a calcium replete diet and progression to intervention with specific anti-bone resorptive drugs such as bisphosphonates and calcium and vitamin D supplements. The lifetime risk of fractures at the hip, spine or forearm in men is 13.1%, and in the elderly hip fractures seriously affect the quality of life. A hip fracture may cost up to £12 000, depending on length of stay, whereas one year's cost of alendronate, which reduces the fracture risk by 50%, is £335. 33, 34 Bisphosphonates are not only of interest because they inhibit osteoclast function, as they may also have direct antineoplastic effects. They inhibit bone invasion by prostatic carcinoma cells 35 and may therefore be useful for the prophylactic treatment of patients with cancers known to preferentially metastasise to bone. 36 
Conclusion
We conclude that in a group of patients treated with LHRH analogues for advanced prostate cancer with resulting hypogonadism, there was a 50% incidence of osteoporosis However, this was similar to patients of similar age living in the community who were not known to have prostate cancer. Bone density is inversely related to fracture risk, with the risk increasing by about 70% for each 1 s.d. decrease in bone density. 37 Therefore, as patients with osteoporosis have bone density values at least 2.5 s.d. below normal, patients on LHRH analogues may be especially at risk of fracture. The patients with advanced prostate cancer had high bone turnover, which may be due to subclinical skeletal metastases or merely represent the effect of low circulating testosterone on bone remodelling. As increased bone turnover is also associated with enhanced risk of osteoporotic fracture in elderly patients, we suggest that patients with prostate cancer treated with androgen deprivation should be considered for anti-bone resorptive treatment to protect against osteoporotic fractures. In particular, younger men, following PSA relapse after radical surgery or radiotherapy who are treated with hormone deprivation, possibly for a longer period of time than elderly patients, should also be included in this strategy. The quality of life issues are especially relevant in this group. Treatment may be undertaken from the beginning of the hormone deprivation treatment with amino bisphosphonates such as alendronate, 38 which increases bone density with decreased bone turnover and additionally may have the ability to promote apoptosis of tumour cells and reduce tumour cell attachment in bone. 39 Patients identified as having osteoporosis in this study are receiving treatment in the Osteoporosis Clinic.
